Using cheap sodium silicate as a silica source and surfactant P123 as a soft template, an environment-friendly mesoporous material, COK-12, was prepared in a near-neutral environment. COK-12 was modified with n-hexane to obtain an H-COK-12 template with a compact and ordered pore structure. In this study, the modified mesoporous material H-COK-12 was used as the template for the first time, and the mesoporous La0.8Sr0.2CoO3 (LSC) catalyst was prepared by nano-casting method combined with sol–gel method. The results showed that the LSC-650 catalyst synthesized at 650 °C for 2 h possessed a large specific surface area (103.46 m2/g) and the highest surface Co4+/Co3+ and Oads/Olat molar ratio. In addition, the CO conversion with the LSC-T (T = 550, 600, 650, 700 °C) samples indicated that the LSC-650 sample had the best catalytic activity (T50 = 145 °C, T90 = 149 °C) and stability.
Bronchial asthma is one of the most common diseases in children′s respiratory system.Its frequent attacks seriously affect children′s health, learning and life, bring great economic burden and mental pressure to families, leading to huge medical and health resources consuming.Many scholars have studied that ADAM33 is a susceptible gene for asthma.This article reviews the relationship between ADAM33 gene polymorphism and asthma, the pathogenesis of ADAM33 in asthma and the new progress in the treatment of ADAM33.
Key words:
ADAM33; Bronchial asthma; Treatment
Abstract Background: The Cyclin D/CDK4/6/Rb axis is dysregulated in breast cancer (BC). Palbociclib (P) is an oral agent that specifically inhibits CDK 4/6 and is FDA approved for hormone-receptor positive (HR+) disease in combination with letrozole or fulvestrant. We performed a Phase II, multi-disease, basket trial of single agent P in patients (pts) with retinoblastoma positive (Rb+), advanced cancer. We now report the full expansion cohort in BC, including a subcohort of pts with HER2+ disease. Methods: Pts with Rb+ BC were eligible for enrollment if they had measureable metastatic disease, adequate organ function and ECOG PS ≥ 1, with no limit on number of prior therapies. Pts were stratified on HER2-status, with a planned HER2-positive (HER2+) cohort, with or without trastuzumab (T). Pts with active brain metastases were excluded. Pts received P 125mg for 21 days on, 7 days off of each 28 day cycle. The protocol was amended on May 12, 2014 to allow concomitant T (given every 3 weeks 6mg/kg) for pts with HER2+ disease. Toxicity was assessed every 28 days. Response was assessed every 2 cycles using RECIST 1.0 guidelines. Results: A total of 62 pts were enrolled: 46 (74.2%) HR+/HER2-, 12% HER2+ (19.3%), and 4 (6.5%) ER/PR/HER2-. 10 of the 12 pts with HER2+ disease received T. As of June 10, 2016 one HER2+ patient (pt) remains on study who is also receiving T. Median age is 58 (range 34-88). Median prior lines of therapy is 6 (range 1-15). Response rates, progression free survival (PFS) and overall survival (OS) are depicted in Table 1 and are stratified by HER2 status and receipt of concomitant T. The most common adverse event was Grade 3 or 4 (G3/4) neutropenia (ntp) which occurred in 30 (48%) pts. There was one episode of febrile ntp in a pt who was progressing and had received 13 prior therapies. Other G3/4 events were leucopenia (n=10, 16.1%) thrombocytopenia (n=9, 14.5%), anemia (n=3, 4.8%). Summary of Results TotalHR+/HER2-HR any/HER2+ with THR any/HER2+ no THR-/HER2-N62*461024PR4 (6.5%)1 (2.2%)2 (20%)1 (50%)0 (0%)SD ≥6mo9 (14.5%)8 (17.4%)1 (10%)0 (0%)0 (0%)SD <6mo22 (35.5%)16 (34.8%)4 (40%)1 (50%)1 (25%)PD26 (41.9%)20 (43.5%)3 (30%)0 (0%)2 (75%)CBR (PR+SD)13 (22%)9 (19.6%)3 (30%)1 (50%)0 (0%)PFS (mo (95% CI))3.5 (2.1, 5.2)3.2 (2.0, 5.2)6.7 (1.6, 17.8)21.2 (5.2, 37.2)1.7 (0.6, 4.8)OS (mo, (95% CI))13.5 (8.9, 14.7)11.9 (7.8, 14.0)17.9 (3.1, NA)NA7.7 (1.5, 13.5)* 1 pt not evaluable for response. HR: hormone receptor; T: trastuzumab; PR: partial response; SD: stable disease; PD: progressive disease; CBR: clinical benefit rate; mo: months; NA: not available Conclusions: P is well tolerated in heavily pretreated pts. Grade 3/4 ntp occurred in 48% of pts and required dose reduction without necessity to add growth factor support; febrile ntp was uncommon. Single agent activity is modest (22% in the overall population) in this heavily pretreated cohort. 3 of the 4 partial responses observed were in pts with HER2+ disease 2 of whom received concurrent T. Prolonged stable disease was observed in 9 pts, 8 of whom had HR+ disease. Given the response rate of 30% in those with HER2+ disease receiving T, and PFS of 6.7 months, further investigation into this combination is warranted. Biomarker studies are underway. Citation Format: Clark AS, Wang X, Troxel A, Burrell J, Feldman M, Lal P, Zhang P, Rosen M, Gallagher M, Ndicu J, Nivar I, Matro J, Domchek SM, Fox KR, O'Dwyer P, DeMichele A. Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-14.
Abstract We previously reported the structure of the placentally derived human cysteine-rich (h crp) cDNA and demonstrated that it encodes a highly conserved and widely distributed zinc finger-like protein. We now report that the expression of both the mouse and human crp genes is induced as a primary response to serum in quiescent Balb/c 3T3 cells and in human fibroblasts. The profile of this primary response is remarkably parallel to that of c-myc in the Balb/c 3T3 cell line. The structure of the 23.2-kilobase h crp gene demonstrates that it is a member of a gene superfamily encoding proteins sharing a highly characteristic 52-amino acid LIM/double-finger motif. The evolutionarily conserved structure of cysteine-rich protein, its structural similarity to a number of developmentally critical proteins, its distinctive tissue distribution, and its primary response to early events in the cell cycle suggest that crp plays an important role in cell function.
Interleukin-8 (IL-8) is a chemokine produced by a variety of cell types involved in atherogenesis and is chemotactic for neutrophils and lymphocytes. A recent study has shown that IL-8 is angiogenic and induces proliferation and chemotaxis of endothelial cells. The present study was undertaken to find out whether IL-8 is also mitogenic and chemotactic for vascular smooth muscle cells. IL-8 induced a concentration-dependent (0.1 to 10 nmol/L) stimulation of DNA synthesis and cell proliferation in both human and rat aortic smooth muscle cells. In addition, IL-8 stimulated smooth muscle cells to produce prostaglandin E2, which can inhibit IL-8-induced smooth muscle cell proliferation. In the presence of indomethacin (5 mumol/L), IL-8 (1 nmol/L) stimulated an increase in human and rat aortic smooth muscle cell number during a 3-day period of incubation by 61 +/- 16% and 59 +/- 7% (n = 4), respectively. IL-8 also increased DNA synthesis in human and rat aortic smooth muscle cells by 98 +/- 10% and 151 +/- 27% (n = 5), respectively. Moreover, IL-8 stimulated rat aortic smooth muscle cell migration by 20-fold over the control value, with an EC50 value of 0.83 nmol/L; this chemotactic activity of IL-8 was also potentiated by indomethacin. Exposure of smooth muscle cells to IL-8 caused rapid and transient expression of the immediate-early genes c-fos and zif268 mRNA.(ABSTRACT TRUNCATED AT 250 WORDS)
